Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Feb 27;17(2):e79769.
doi: 10.7759/cureus.79769. eCollection 2025 Feb.

Clonidine to the Rescue: A Novel Approach to Refractory Diabetic Gastroparesis in the Postoperative Setting

Affiliations
Case Reports

Clonidine to the Rescue: A Novel Approach to Refractory Diabetic Gastroparesis in the Postoperative Setting

Marsida Kasa et al. Cureus. .

Abstract

Gastroparesis is a recognized complication in patients with long-standing diabetes mellitus (DM), characterized by delayed gastric emptying without mechanical obstruction. Common symptoms include nausea, vomiting, bloating, and early satiety, all of which can significantly impair both quality of life and glycemic control. Standard therapies, such as prokinetic agents (e.g., metoclopramide and domperidone) and antiemetics (e.g., ondansetron), are commonly used but may fail in refractory cases, prompting an investigation into alternative treatments. Clonidine, an α2-adrenergic agonist traditionally prescribed for diabetic diarrhea, has demonstrated promise in managing autonomic dysfunction and thus may represent a novel option for gastroparesis management. This case report describes a 65-year-old man with type 2 DM and stage 3 chronic kidney disease (CKD), presumed secondary to diabetic nephropathy, retinopathy, and peripheral neuropathy. Following orthopedic surgery, he developed severe postoperative vomiting, leading to the discontinuation of his antihypertensive therapy. After two days without antihypertensive medications, a hypertensive crisis occurred (blood pressure, 210/120 mmHg), accompanied by an acute rise in serum creatinine to 5 mg/dL, oliguria, and generalized edema. The ongoing vomiting further contributed to dehydration and worsening acute renal dysfunction. Despite receiving continuous veno-venous hemodialysis (CVVHD) for 48 hours and antiemetic treatment with metoclopramide and ondansetron for one week, his nausea and vomiting persisted. Other etiologies were excluded, and a diagnosis of diabetic gastroparesis was established. Initiation of clonidine at a dose of 100 mcg twice daily produced marked symptom improvement within 48 hours, enabling the resumption of regular oral intake and stabilization of renal function. The patient was discharged in stable condition and remained asymptomatic at his six-month follow-up appointment. This case underscores the potential of clonidine as an adjunct treatment for patients with refractory diabetic gastroparesis, highlighting its impact on autonomic regulation and symptom alleviation. Further studies are warranted to substantiate its efficacy and safety in larger patient populations.

Keywords: acute renal injury; chronic diarrea; diabetic complications; fluid status; hypertension and therapy.

PubMed Disclaimer

Conflict of interest statement

Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

    1. Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population. Choung RS, Locke GR, Schleck CD, Zinsmeister AR, Melton LJ, Talley NJ. https://10.1038/ajg.2011.310. Am J Gastroenterol. 2012;107:82–88. - PMC - PubMed
    1. Gastroparesis might not be uncommon in patients with diabetes mellitus in a real-world clinical setting: a cohort study. Lee J, Park HL, Park SY, et al. https://doi.org/10.1186/s12876-023-03106-6. BMC Gastroenterol. 2024;24:30. - PMC - PubMed
    1. Obesity and symptoms suggestive of gastroparesis in patients with type 2 diabetes and neuropathy. Boaz M, Kislov J, Dickman R, Wainstein J. https://doi.org/10.1016/j.jdiacomp.2011.06.005. J Diabetes Complications. 2011;25:325–328. - PubMed
    1. Gastrointestinal complications of diabetes mellitus. Krishnan B, Babu S, Walker J, Walker AB, Pappachan JM. https://doi.org/10.4239/wjd.v4.i3.51. World J Diabetes. 2013;4:51–63. - PMC - PubMed
    1. Diabetic gastroparesis: an overview of pathogenesis, clinical presentation and novel therapies, with a focus on ghrelin receptor agonists. Petri M, Singh I, Baker C, Underkofler C, Rasouli N. https://doi.org/10.1016/j.jdiacomp.2020.107733. J Diabetes Complications. 2021;35:107733. - PubMed

Publication types

LinkOut - more resources